Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Inotuzumab
DRUG
2 trials
Sponsors
Novartis Pharmaceuticals
, St. Jude Children's Research Hospital
Conditions
Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Phase 2
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Recruiting
NCT06533748
St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Start: 2025-01-23
End: 2034-05-01
Target: 128
Updated: 2026-07-16
Phase 3
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Withdrawn
NCT03628053
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
Start: 2020-06-05
End: 2026-01-07
Updated: 2020-07-09
Related Papers
Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.
2021-02-15
6 citations
Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody
Cancers
2019-12-06
17 citations